In PCa, a recent clinical study reported that use of PDE5 inhibitors may be clinically associated with increased biochemical recurrence after radical prostatectomy [49] although contradictory results were reported in other studies [50]. The gene discussed is PDE5A; the disease is posterior cortical atrophy.